PIOTR KULESZA
Medical Practice in Baltimore, MD
License number
Pennsylvania MD420745
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
2
Baltimore, MD 21218
Pennsylvania
Pennsylvania
Personal information
See more information about PIOTR KULESZA at radaris.comName
Address
Phone
1220 Northview Rd, Baltimore, MD 21218
Professional information
Rapid Prognostic Assay For Malignancies Treated With Epidermal Growth Factor Receptor
US Patent:
2006018, Aug 24, 2006
Filed:
Aug 31, 2005
Appl. No.:
11/217657
Inventors:
Piotr Kulesza - Baltimore MD, US
Antonio Jimeno - Baltimore MD, US
Manuel Hidalgo - Baltimore MD, US
Douglas Clark - Baltimore MD, US
Erik Kincaid - Baltimore MD, US
Antonio Jimeno - Baltimore MD, US
Manuel Hidalgo - Baltimore MD, US
Douglas Clark - Baltimore MD, US
Erik Kincaid - Baltimore MD, US
Assignee:
The Johns Hopkins University - Baltimore MD
International Classification:
C12Q 1/68
US Classification:
435006000
Abstract:
A molecular assay for determining the sensitivity or resistance of malignancies to chemotherapy prior to initiation of chemotherapy and which also allows for monitoring the therapeutic effects of the chemotherapy during treatment. The molecular assay measures tumor response to therapy with EGFR modulators and utilizes tumor mRNA as a starting material and a quantitative measurement of c-fos expression as an analytical endpoint.
Dr. Piotr Kulesza, Birmingham AL - MD (Doctor of Medicine)
Specialties:
Cytopathology
Address:
619 19Th St S, Birmingham 35233
(205) 934-6600 (Phone)
UNIVERSITY OF ALABAMA HOSPITAL
619 19Th St S, Birmingham 35233
(205) 934-9999 (Phone), (205) 975-9694 (Fax)
JOHNS HOPKINS HOSPITAL
600 N Wolfe St, Baltimore 21287
(410) 955-5080 (Phone), (410) 955-1464 (Fax)
(205) 934-6600 (Phone)
UNIVERSITY OF ALABAMA HOSPITAL
619 19Th St S, Birmingham 35233
(205) 934-9999 (Phone), (205) 975-9694 (Fax)
JOHNS HOPKINS HOSPITAL
600 N Wolfe St, Baltimore 21287
(410) 955-5080 (Phone), (410) 955-1464 (Fax)
Certifications:
Anatomic & Clinical Pathology, 2003, Cytopathology, 2008
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
619 19Th St S, Birmingham 35233
UNIVERSITY OF ALABAMA HOSPITAL
619 19Th St S, Birmingham 35233
JOHNS HOPKINS HOSPITAL
600 N Wolfe St, Baltimore 21287
University of Alabama Hospital
1802 6Th Ave South, Birmingham 35233
UNIVERSITY OF ALABAMA HOSPITAL
619 19Th St S, Birmingham 35233
JOHNS HOPKINS HOSPITAL
600 N Wolfe St, Baltimore 21287
University of Alabama Hospital
1802 6Th Ave South, Birmingham 35233
Education:
Medical School
Washington Center / School of Medicine
Graduated: 1995
Johns Hopkins University School Med
Washington Center / School of Medicine
Graduated: 1995
Johns Hopkins University School Med
Rapid Prognostic Assay For Malignancies Treated With Epidermal Growth Factor Receptor
US Patent:
2008029, Nov 27, 2008
Filed:
May 22, 2008
Appl. No.:
12/125790
Inventors:
Piotr Kulesza - Baltimore MD, US
Antonio Jimeno - Baltimore MD, US
Manuel M. Hidalgo - Baltimore MD, US
Douglas P. Clark - Baltimore MD, US
Erik A. Kincaid - Baltimore MD, US
Antonio Jimeno - Baltimore MD, US
Manuel M. Hidalgo - Baltimore MD, US
Douglas P. Clark - Baltimore MD, US
Erik A. Kincaid - Baltimore MD, US
International Classification:
C12Q 1/68, G01N 33/574
US Classification:
435 6, 435 723
Abstract:
A molecular assay for determining the sensitivity or resistance of malignancies to chemotherapy prior to initiation of chemotherapy and which also allows for monitoring the therapeutic effects of the chemotherapy during treatment. The molecular assay measures tumor response to therapy with EGFR modulators and utilizes tumor mRNA as a starting material and a quantitative measurement of c-fos expression as an analytical endpoint.